Home » Stocks » ENOB

Enochian Biosciences, Inc. (ENOB)

Stock Price: $3.28 USD 0.11 (3.47%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $3.30 +0.02 (0.61%) Jan 22, 7:27 PM
Market Cap 152.97M
Revenue (ttm) n/a
Net Income (ttm) -9.73M
Shares Out 46.61M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $3.28
Previous Close $3.17
Change ($) 0.11
Change (%) 3.47%
Day's Open 3.17
Day's Range 3.12 - 3.30
Day's Volume 133,519
52-Week Range 2.08 - 6.06

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 months ago

LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences , a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, t...

Benzinga - 7 months ago

Shares of Enochian Biosciences Inc (NASDAQ: ENOB) were trading more than 75% higher Monday in reaction to the company's announcement regarding a positive FDA meeting regarding its HIV candidate.

24/7 Wall Street - 7 months ago

Enochian BioSciences Inc. (NASDAQ: ENOB) shares more than doubled to start out the week after the company received a critical update from the U.S.

GlobeNewsWire - 7 months ago

Company encouraged by strong alignment with views of FDA’s CBER regarding ENOB-HV-01 LOS ANGELES, June 08, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company fo...

GlobeNewsWire - 8 months ago

• First presentation of a novel approach to potentially cure HIV   -  An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells

GlobeNewsWire - 10 months ago

LOS ANGELES, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on genetically modified cellular and immune therapy for infectious diseases and cancer, announces that ...

GlobeNewsWire - 11 months ago

LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized th...

GlobeNewsWire - 1 year ago

- Gregg Alton, the former interim CEO of Gilead Sciences, a company he served in many key roles during his more than 20 year tenure, and; - Carol Brosgart, MD, Clinical Professor of Medici...

GlobeNewsWire - 1 year ago

LOS ANGELES, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces that important scientific...

Seeking Alpha - 1 year ago

Enochian Biosciences Is A House Of Cards - The Pipeline Is Entirely Pre-Clinical And Management Has A Questionable History

About ENOB

Enochian Biosciences, a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
ENOB
Full Company Profile

Financial Performance

Financial Statements